MX2022013021A - Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. - Google Patents
Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.Info
- Publication number
- MX2022013021A MX2022013021A MX2022013021A MX2022013021A MX2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A MX 2022013021 A MX2022013021 A MX 2022013021A
- Authority
- MX
- Mexico
- Prior art keywords
- lung
- leriglitazone
- interstitial
- treating
- inflammation
- Prior art date
Links
- 208000029523 Interstitial Lung disease Diseases 0.000 title abstract 2
- 206010035664 Pneumonia Diseases 0.000 title 1
- OXVFDZYQLGRLCD-SJKOYZFVSA-N leriglitazone Chemical compound N1=CC([C@H](O)C)=CC=C1CCOC(C=C1)=CC=C1C[C@@H]1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-SJKOYZFVSA-N 0.000 title 1
- 229940121457 leriglitazone Drugs 0.000 title 1
- 210000004072 lung Anatomy 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- JMLKLMFMQRAJNI-UHFFFAOYSA-N 5-[[4-[2-(5-acetylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(C(=O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 JMLKLMFMQRAJNI-UHFFFAOYSA-N 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382356 | 2020-04-30 | ||
| PCT/IB2021/053651 WO2021220250A1 (en) | 2020-04-30 | 2021-04-30 | Leriglitazone for treating lung inflammation and interstitial lung disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013021A true MX2022013021A (es) | 2023-01-16 |
Family
ID=70779625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013021A MX2022013021A (es) | 2020-04-30 | 2021-04-30 | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230172921A1 (https=) |
| EP (1) | EP4142720A1 (https=) |
| JP (1) | JP2023525981A (https=) |
| KR (1) | KR20230035522A (https=) |
| CN (1) | CN116390725A (https=) |
| AU (1) | AU2021265345A1 (https=) |
| BR (1) | BR112022021951A2 (https=) |
| CA (1) | CA3180351A1 (https=) |
| IL (1) | IL297771A (https=) |
| MX (1) | MX2022013021A (https=) |
| WO (1) | WO2021220250A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4642456A1 (en) * | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| WO2024231881A2 (en) * | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590774A (en) * | 2008-08-07 | 2012-09-28 | Pulmagen Therapeutics Inflammation Ltd | Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases |
| WO2010150014A1 (en) * | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| WO2011047048A1 (en) * | 2009-10-14 | 2011-04-21 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| WO2011073662A1 (en) * | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| EA202091120A3 (ru) | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы |
| JP7040798B2 (ja) * | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン |
| CN112823004A (zh) * | 2018-06-06 | 2021-05-18 | 米尼奥尔克斯治疗有限公司 | 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途 |
-
2021
- 2021-04-30 US US17/997,393 patent/US20230172921A1/en not_active Abandoned
- 2021-04-30 EP EP21723015.0A patent/EP4142720A1/en not_active Withdrawn
- 2021-04-30 IL IL297771A patent/IL297771A/en unknown
- 2021-04-30 MX MX2022013021A patent/MX2022013021A/es unknown
- 2021-04-30 CN CN202180043546.3A patent/CN116390725A/zh active Pending
- 2021-04-30 BR BR112022021951A patent/BR112022021951A2/pt unknown
- 2021-04-30 KR KR1020227042096A patent/KR20230035522A/ko not_active Abandoned
- 2021-04-30 AU AU2021265345A patent/AU2021265345A1/en not_active Abandoned
- 2021-04-30 WO PCT/IB2021/053651 patent/WO2021220250A1/en not_active Ceased
- 2021-04-30 CA CA3180351A patent/CA3180351A1/en active Pending
- 2021-04-30 JP JP2022566063A patent/JP2023525981A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3180351A1 (en) | 2021-11-04 |
| WO2021220250A1 (en) | 2021-11-04 |
| IL297771A (en) | 2022-12-01 |
| CN116390725A (zh) | 2023-07-04 |
| JP2023525981A (ja) | 2023-06-20 |
| AU2021265345A1 (en) | 2022-12-08 |
| KR20230035522A (ko) | 2023-03-14 |
| EP4142720A1 (en) | 2023-03-08 |
| US20230172921A1 (en) | 2023-06-08 |
| BR112022021951A2 (pt) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279183A (en) | Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione | |
| MX2022013021A (es) | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| AU2002246397A1 (en) | Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence | |
| JP2014528450A5 (https=) | ||
| IL279186A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts | |
| SE0301232D0 (sv) | Novel use | |
| JP2016512511A5 (https=) | ||
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2004517054A5 (https=) | ||
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| CY1124116T1 (el) | 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος | |
| AR047541A1 (es) | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas | |
| SI3801515T1 (sl) | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| HUE059604T2 (hu) | Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására | |
| AU2001292046A1 (en) | Use of a ppar delta activator for treating inflammatory conditions | |
| US20170239242A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis | |
| RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
| HK40050840A (en) | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | |
| IL287894A (en) | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in the prevention of pain and/or pain treatment in animals | |
| EA200701681A1 (ru) | Пероральная лекарственная форма, содержащая росиглитазон | |
| SE0402591D0 (sv) | Novel use | |
| AR023566A1 (es) | Un procedimiento para el dihidrato del hidrocloruro derivado de la tiazolidina-2,4-diona |